Role of adropin in arterial stiffening associated with obesity and type 2 diabetes
Thomas J. Jurrissen, Francisco I. Ramirez‐Perez, Francisco J. Cabral-Amador, Rogério N. Soares, Ryan Pettit‐Mee, Edgar Betancourt-Cortes, Neil J. McMillan, Neekun Sharma, Helena Rocha, Shumpei Fujie, Mariana Morales‐Quinones, Yoskaly Lazo‐Fernandez, Andrew A. Butler, Subhashis Banerjee, Harold S. Sacks, Jamal A. Ibdah, Elizabeth J. Parks, R. Scott Rector, Camila Manrique‐Acevedo, Luis A. Martinez‐Lemus, Jaume Padilla
Abstract
Arterial stiffening, a characteristic feature of obesity and type 2 diabetes (T2D), contributes to the development and progression of cardiovascular diseases. Herein we establish that adropin is decreased in obese and T2D models and furthermore provide evidence that reduced adropin may directly contribute to arterial stiffening. Collectively, findings from this work support the notion that "hypoadropinemia" should be considered as a putative target for the prevention and treatment of arterial stiffening in obesity and T2D.